Bavarian on lacking coronavirus vaccine funding: Sponsors prioritize speed over quality

Bavarian Nordic and Adaptvac have yet to acquire the necessary financing for their vaccine against Covid-19. Bavarian maintains that it has an excellent candidate at hand.

Photo: Bavarian Nordic / PR

Technically, a postponed phase III trial with a vaccine candidate for the respiratory virus RSV should have cleared space for Bavarian Nordic to do clinical trials with the vaccine for Covid-19 for which Bavarian Nordic has acquired the rights from the smaller Danish company Adaptvac.

There's just one problem: Bavarian Nordic has not been successful in procuring the external financing the firm has established as a requirement for getting started on its phase II or III studies with the vaccine.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs